FourThought Financial Partners LLC Has $3.57 Million Stock Position in Zoetis Inc. $ZTS

FourThought Financial Partners LLC reduced its holdings in Zoetis Inc. (NYSE:ZTS) by 13.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 22,917 shares of the company’s stock after selling 3,469 shares during the period. FourThought Financial Partners LLC’s holdings in Zoetis were worth $3,574,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis during the first quarter worth approximately $25,000. 1248 Management LLC purchased a new stake in Zoetis in the 1st quarter worth approximately $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the 1st quarter valued at $29,000. REAP Financial Group LLC boosted its stake in shares of Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the period. Finally, NewSquare Capital LLC grew its holdings in shares of Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE ZTS opened at $122.80 on Tuesday. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $181.85. The stock’s 50-day moving average is $137.28 and its two-hundred day moving average is $149.86. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04. The firm has a market cap of $54.12 billion, a P/E ratio of 21.14, a price-to-earnings-growth ratio of 2.31 and a beta of 0.90.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.08. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.42 billion. During the same quarter in the prior year, the company posted $1.58 EPS. The firm’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.6%. The ex-dividend date is Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is 33.67%.

Analysts Set New Price Targets

Several analysts recently issued reports on ZTS shares. Piper Sandler increased their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Morgan Stanley lowered their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating on the stock in a research note on Monday, November 10th. JPMorgan Chase & Co. cut their price target on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Finally, Stifel Nicolaus lowered their price target on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Six research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $178.89.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.